Atrial fibrillation and the 'other drug problem': Reducing non-adherence with technology

European Heart Journal

Volumn 34, Issue 27, 2013, Pages 2031-2033

  Nerini, Erika ^a   Grip, Laura ^b   Camm, A John ^c   Giugliano, Robert P ^b  

^a FBCommunication   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BEHAVIOR CHANGE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DRUG HALF LIFE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INTERACTIVE VOICE RESPONSE SYSTEM; INTERNATIONAL NORMALIZED RATIO; MEDICARE; NOTE; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT REFUSAL;

ADMINISTRATION, ORAL; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; REMINDER SYSTEMS; TELEMEDICINE;

EID: 84880542525     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht174     Document Type: Note

References (20)

1. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-47. (Pubitemid 351160875)
2. World Health Organization 2003. Adherence to long term therapies: evidence for action. http://www.who.int/chp/knowledge/publications/adherence- report/en/ (10 September 2012).
3. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherencetodrug therapy and mortality. Br Med J 2006;333:15-20.
4. Munger MA, Van Tassel BW, LaFleur J. Medication non-adherence: an unrecognized cardiovascular risk factor. MedGenMed 2007;9:58.
5. Singh S. Costs and clinical consequences of suboptimal atrial fibrillation management. Clinico Econ Outcome Res 2012;4:79-90.
6. Aslam F, Haque A, Foody JM. Medication non-adherence: the other drug problem. Hot Topics Cardiol 2012;7:7-14.
7. NICE. Costing Statement: medicine adherence: involving patients in decisions about prescribed medicines and supporting adherence. January 2009. http://guidance.nice.org.uk/CG76/CostingStatement/pdf/English (10 September 2012).
8. PGEU Policy statement. Targeting adherence. Improving patient outcomes in Europe through community pharmacists' intervention. 2008. http://www.pgeu.eu/ en/policy/5-adherence.html (10 September 2012).
9. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. ESC Committee for Practice Guidelines (CPG), Document Reviewers. 2012 Focused updateof the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
10. Ringborg A, Nieuwlaat R, Lindgren P, Jönsson B, Fidan D, Maggioni AP, Lopez-Sendon J, Stepinska J, Cokkinos DV, Crijns HJ. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 2008;10:403-411. (Pubitemid 351767678)
11. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006;9:348-356. (Pubitemid 44337788)
12. Waterman AD, Milligan PE, Bayer L, Banet GA, Gatchel SK, Gage BF. Effect of warfarin non-adherence on control of the international normalized ratio. Am J Health Syst Pharm 2004;61:1258-1264. (Pubitemid 39481461)
13. Song X, Sander SD, VarkerH, Amin A. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs 2012;12:245-253.
14. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. RE-LY Steering Committee and Investigators. Dabigatran versus warfarininpatients with atrial fibrillation. NEngl J Med 2009;361:1139-1151.
15. Soumerai SB, Pierre-Jacques M, Zhang F, Ross-Degnan D, Adams AS, Gurwitz J, Adler G, Safran DG. Cost-related medication nonadherence among elderly and disabled medicare beneficiaries: a national survey 1 year before the medicare drug benefit. Arch Intern Med 2006;166:1829-1835. (Pubitemid 44455164)
16. Rinfret S. Telephone Contacts to Improve Adherence to Dual Anti-Platelet Therapy Following Drug-Eluting Stent Implantation: A Randomized Controlled-Trial. SCAI Scientific Sessions, May 2012 Las Vegas, NV. Abstract A-017.
17. Zurovac D, Sudoi RK, Akhwale WS, Ndiritu M, Hamer DH, Rowe AK, Snow RW. The effect of mobile phone text-message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster randomised trial. Lancet 2011; 378:795-803.
18. Stockwell MS, Kharbanda EO, Martinez RA, Vargas CY, Vawdrey DK, Camargo S. Effect of a text messaging intervention on influenza vaccination in a urban, low-income pediatric and adolescent population: a randomized controlled trial. JAMA 2012;307:1702-1708.
19. Vollmer WM, Feldstein A, Smith DH, Dubanoski JP, Waterbury A, Schneider JL, Clark SA, Rand C. Use of health information technology to improve medication adherence. Am J Manag Care 2011;17(12 Spec No.):SP79-SP87.
20. Rodrigues R, Shet A, Antony J, Sidney K, Arumugam K, Krishnamurthy S, D'Souza G, Decosta A. Supporting adherence to antiretroviral therapy with mobile phone reminders: results from a cohort in South India. PLoS One 2012;7:e40723 (Epub 2012 Aug 27).